SCHEMBL5880258

SCHEMBL5880258

CCc1cc(O)cc(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.65
CALM1 P0DP23 6/20 0.61
GABRA1 P14867 1/20 0.58
GABRG2 P18507 1/20 0.58
GABRB3 P28472 1/20 0.58
GABRA3 P34903 1/20 0.58
GABRA2 P47869 1/20 0.58
GABRB2 P47870 1/20 0.58
PTPN1 P18031 1/20 0.53
NOS2 P35228 1/20 0.53
TTR P02766 1/20 0.48
CYP1A1 P04798 1/20 0.48
ALOX5 P09917 1/20 0.48
CYP1B1 Q16678 1/20 0.48
AKR1B1 P15121 2/20 0.47
CYP3A4 P08684 3/20 0.46
ABL1 P00519 1/20 0.45
ABCB1 P08183 1/20 0.45
BCR P11274 1/20 0.45
BACE1 P56817 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11258820 0.84 ALDH1A1 (0.53) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL88823 0.84 ALDH1A1 (0.61) PTGS2CALM1CYP1A1CYP1B1AKR1B1
SCHEMBL9773883 0.83 PTGS2 (0.77) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL30195497 0.83 PTGS2 (0.77) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL10536298 0.83 CALM1 (0.61) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL29389280 0.83 CALM1 (0.61) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL1650366 0.83 CALM1 (0.61) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL20165013 0.81 CALM1 (0.59) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL8048694 0.81 LTA4H (0.48) PTGS2CALM1GABRA1GABRG2GABRB3
SCHEMBL19663703 0.81 CALM1 (0.59) PTGS2CALM1GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119541903-B Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-06-13 CN claimed
CN-119541903-A Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-02-28 CN claimed
CN-119541903-B Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-06-13 CN disclosed
CN-119541903-A Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-02-28 CN disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 WO disclosed
US-20180090787-A1 SOLID ELECTROLYTE COMPOSITION, ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY, ALL-SOLID STATE SECONDARY BATTERY, AND METHODS FOR MANUFACTURING ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY AND ALL-SOLID STATE SECONDARY BATTERY FUJIFILM CORPORATION (JP) 2018-03-29 US disclosed
EP-2970224-B1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS INC (US) 2017-09-06 EP disclosed
EP-2537826-B1 Fluorination of aromatic ring systems NUTECH VENTURES (US) 2017-03-08 EP disclosed
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-20160368946-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2016-12-22 US disclosed
US-9434761-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-09-06 US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 EP disclosed
US-7045652-B2 From alkyl boronic esters; intermediates in the preparation of 2-amino-6-(substituted-4-phenoxy)-substituted-pyridines PFIZER INC (US) 2006-05-16 US disclosed
EP-1519940-A1 SUBSTITUTED ARYL BORONIC ACIDS, THEIR PREPARATION AND THEIR PRECURSORS Pfizer Products Inc. (US) 2005-04-06 EP disclosed
US-20040038940-A1 Processes for preparing substituted aryl boronic acids PFIZER INC. 2004-02-26 US disclosed
WO-2004005301-A1 SUBSTITUTED ARYL BORONIC ACIDS, THEIR PREPARATION AND THEIR PRECURSORS PFIZER PRODUCTS INC. (US) 2004-01-15 WO disclosed
WO-2003068233-A1 NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES PFIZER LIMITED (GB) 2003-08-21 WO disclosed
US-5075415-A ADHESIVE COMPOSITION FOR FIBROUS MATERIALS BASED ON PHENOL-AMINOPHENOL-FORMALDEHYDE CONDENSATION PRODUCTS BRIDGESTONE CORPORATION (JP) 1991-12-24 US disclosed
EP-0298704-A2 Adhesive composition for fibrous materials and process of its preparation Bridgestone Corporation (JP) 1989-01-11 EP disclosed
US-4378453-A ALKOXYPHENOL DERIVATIVE-RESORCIN DERIVATIVE-FORMALDEHYDE COCONDENSATE BRIDGESTONE TIRE CO., LTD. (JP) 1983-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368946-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP PTGS2 485/4885CALM1 4369/4885GABRA1 3586/4885
US-20040038940-A1 Processes for preparing substituted aryl boronic acids NOS1, NOS2, CYP1B1 PTGS2 446/4885CALM1 2860/4885GABRA1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.